SMIN

2,360

+2.88%↑

SMIN

2,360

+2.88%↑

SMIN

2,360

+2.88%↑

SMIN

2,360

+2.88%↑

SMIN

2,360

+2.88%↑

Search

Syncona Ltd

Deschisă

86.9 -5.34

Rezumat

Modificarea prețului

24h

Curent

Minim

86.7

Maxim

90.1

Indicatori cheie

By Trading Economics

Venit

-25M

Vânzări

20M

Marjă de profit

-127.345

Angajați

1,215

EBITDA

-25M

Dividende

By Dow Jones

Următoarele câștiguri

18 iun. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

555M

Deschiderea anterioară

92.24

Închiderea anterioară

86.9

Syncona Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

31 mar. 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Nike, RH, NCino

31 mar. 2026, 22:35 UTC

Câștiguri

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 apr. 2026, 00:00 UTC

Achiziții, Fuziuni, Preluări

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar. 2026, 23:50 UTC

Achiziții, Fuziuni, Preluări

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar. 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar. 2026, 23:33 UTC

Market Talk
Evenimente importante

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar. 2026, 23:21 UTC

Câștiguri

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar. 2026, 23:14 UTC

Market Talk
Câștiguri

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar. 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss Widens >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar. 2026, 22:36 UTC

Câștiguri

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar. 2026, 21:46 UTC

Achiziții, Fuziuni, Preluări

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar. 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar. 2026, 21:35 UTC

Câștiguri

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar. 2026, 21:33 UTC

Achiziții, Fuziuni, Preluări

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar. 2026, 21:33 UTC

Câștiguri

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar. 2026, 21:32 UTC

Câștiguri

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar. 2026, 21:28 UTC

Câștiguri

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar. 2026, 21:26 UTC

Câștiguri

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar. 2026, 21:25 UTC

Câștiguri

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar. 2026, 21:24 UTC

Market Talk
Câștiguri

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar. 2026, 21:22 UTC

Câștiguri

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar. 2026, 21:22 UTC

Câștiguri

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar. 2026, 21:21 UTC

Câștiguri

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar. 2026, 21:20 UTC

Câștiguri

Nike CEO: Converse Remains Important to Portfolio

Comparație

Modificare preț

Syncona Ltd Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

$

Despre Syncona Ltd

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
help-icon Live chat